Eli Lilly (LLY.N), opens new tab will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday.
• 12.5 mg & 15 mg doses now available in single-dose vials.
• Flat pricing of $499/month or less, regardless of insurance.
• Doctors can begin prescribing higher-dose vials starting July 7.
• Lilly & Novo Nordisk offering discounted vials to increase accessibility.
• The LillyDirect website was launched last year to help patients directly order some drugs.
• In February, the U.S. drugmaker reduced the price of Zepbound vials and expanded the range of doses for patients who choose to pay cash through the drugmaker's direct-to-consumer website.
• Dropping Zepbound from some reimbursement lists starting July 1, 2025.
• Prioritizing Wegovy after securing a more favorable price from Novo Nordisk.
• Lilly vs. Novo Nordisk—both competing in the $150 billion obesity drug market.
• Lilly has overtaken Novo, despite Novo’s initial first-mover advantage.
• Compounding pharmacies had been allowed to produce hundreds of thousands of doses of their versions when the branded drugs were in shortage.
• However, the U.S. Food and Drug Administration has since banned sales of the copies.
The companies have also been offering the drugs on several telehealth platforms.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!